Vaccine Contract Manufacturing Market Expansion is $13.16 Billion with 12.4% CAGR by 2032

Vaccine Contract Manufacturing Market Size Worth $13.16 Billion By 2032 | CAGR: 12.4%

The global vaccine contract manufacturing market size is expected to reach USD 13.16 billion by 2032, according to a new study by Polaris Market Research. The report “Vaccine Contract Manufacturing Market Share, Size, Trends, Industry Analysis Report, By Vaccine Type (Inactivated Vaccine, DNA Vaccines, Attenuated Vaccine, Toxoid Vaccines, Subunit Vaccines); By Application; By Process; By Region; Segment Forecast, 2024- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Pharmaceutical and biopharmaceutical companies are strategically prioritizing their core competencies to navigate the escalating price pressures. Consequently, there is a growing inclination towards contract manufacturing.

However, vaccine production presents a complex challenge for manufacturers as they strive to guarantee safety, effectiveness, and consistency. The vaccine contract manufacturing market is driven by a diverse range of services encompassing production processes, the establishment and operation of manufacturing facilities, cell line development, fermentation, process refinement, and analytical characterization. These services collectively play a pivotal role in driving the market's substantial growth on a worldwide level.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below:

Vaccination plays an important role in enhancing both human and veterinary health. It not only diminishes reliance on antibiotics but also serves as a potent deterrent against various diseases. The escalating recognition of its manifold advantages, which include safeguarding against severe illnesses and infectious conditions, is fueling the call for widespread immunization initiatives and inoculation programs. In tandem with this, the cognizance of the substantial capital outlay needed for production has prompted major pharmaceutical entities to opt for outsourcing in the realm of vaccine manufacturing.

However, in low-resource countries, the shortage of equipment and proficient labor for vaccine production is a significant factor driving the expansion of the global vaccine contract manufacturing market. Additionally, the introduction of advanced expression systems such as EB66 and GPEx, along with innovative cell culture media platforms, is providing substantial support for market growth. Furthermore, the surging instances of COVID-19 in various nations have prompted vaccine developers to engage in outsourcing agreements with Contract Manufacturing Organizations (CMOs), fostering a positive trajectory for market advancement.

Vaccine Contract Manufacturing Market Report Highlights

  • The Inactivated Vaccine segment is expected to witness the fastest CAGR during the forecast period on account of better efficiency.
  • The veterinary segment held a significant share in revenue share in 2022, which is mainly driven by increased utilization of CMOs in the production of animal vaccinations.
  • In 2022, the downstream segment held the largest market share due to technological advancements and innovation.
  • In 2022, the North American region held the largest market share, owing to exponential growth in technology and rising R&D investments.
  • The global key market players include Fujifilm Diosynth Biotechnologies, IDT Biologika GmbH, KBI Biopharma, Lonza Group, Merck KGaA, and more.

Polaris Market Research has segmented the vaccine contract manufacturing market report based on vaccine type, application, process, and region:

Vaccine Contract Manufacturing, Vaccine Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Inactivated Vaccine
  • DNA Vaccines
  • Attenuated Vaccine
  • Toxoid Vaccines
  • Subunit Vaccines

Vaccine Contract Manufacturing, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Human
  • Veterinary

Vaccine Contract Manufacturing, Process Outlook (Revenue - USD Billion, 2019 - 2032)

  • Upstream
  • Downstream

Vaccine Contract Manufacturing, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Vaccine Contract Manufacturing Market Report Scope

Report Attributes


Market size value in 2024

USD 5.16 billion

Revenue forecast in 2032

USD 13.16 billion


12.4% from 2024 – 2032

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD billion and CAGR from 2024 to 2032

Segments covered

By Vaccine Type, By Application, By Process, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa


Report customization as per your requirements with respect to countries, region and segmentation.

For Specific Research Requirements

Request for Customized Report

License and Pricing

Purchase Report Sections

  • Regional analysis
  • Segmentation analysis
  • Industry outlook
  • Competitive landscape
Request for Discount Pricing